FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Links shared publicly online about this topic.

35
total visits

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

View full resource at news-medical.net

Tags: Constipation, Pain, Diet and Nutrition, Drug, Pharma, FDA

Most Recently Shared on August 30, 2011 at 12:45 pm By:

News-Medical.Net

Oncology News: FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation: P... http://t.co/fynrwY0

8 months ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

sNDA Accepted for Relistor for Opioid Induced Constipation - MPR

empr.com — “Progenics Pharmaceuticals and Salix Pharmaceuticals announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Relistor (methylnaltrexone bromide) Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.” View full resource at empr.com